JPH0539257A - Compound and its production - Google Patents

Compound and its production

Info

Publication number
JPH0539257A
JPH0539257A JP19776291A JP19776291A JPH0539257A JP H0539257 A JPH0539257 A JP H0539257A JP 19776291 A JP19776291 A JP 19776291A JP 19776291 A JP19776291 A JP 19776291A JP H0539257 A JPH0539257 A JP H0539257A
Authority
JP
Japan
Prior art keywords
compound
formula
culture
chemical
culturing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP19776291A
Other languages
Japanese (ja)
Inventor
Shinji Tsuyunashi
慎二 露無
Kazuo Kumagai
和夫 熊谷
Nariyasu Nabeshima
成泰 鍋島
Mitsunori Kato
三典 加藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Chemical Co Ltd
Original Assignee
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co Ltd filed Critical Sumitomo Chemical Co Ltd
Priority to JP19776291A priority Critical patent/JPH0539257A/en
Publication of JPH0539257A publication Critical patent/JPH0539257A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PURPOSE:To obtain a new compound from a bacterium belonging to the genus Pseudomonas, useful as a compound for a medicine or agricultural chemical, having antimicrobial activity and antifungal activity. CONSTITUTION:A compound shown by formula I (R is H or SCH3), namely antibiotic T1, 801A shown by formula II and antibiotic T1, 801C shown by formula III. The compound shown by formula I, for example, is obtained by culturing SC-1,801 strain (FERM P-12,327) using various kinds of media containing a carbon source, a nitrogen source, inorganic substances, etc., at 28-33 deg.C at pH6-8 and by collecting from the culture mixture.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、化合物およびその製造
方法に関する。
FIELD OF THE INVENTION The present invention relates to a compound and a method for producing the same.

【0002】[0002]

【従来の技術】シュードモナス属に属する微生物が生産
する化合物としては、ピオルテオリン(R. Takeda, J.
Am. Chem. Soc., 80, 4749, 1958)、ピロールニトリン
(K.Arima et al., Agri. Biol. Chem., 28, 575, 196
4 )、シュードモニックアシド(E. B. Chain et al.,
J. Chem. Soc., Perkin Trans. I, 294, 1977)などが
知られている。
2. Description of the Related Art As a compound produced by a microorganism belonging to the genus Pseudomonas, pioluteolin (R. Takeda, J.
Am. Chem. Soc., 80 , 4749, 1958), pyrrole nitrin (K.Arima et al., Agri. Biol. Chem., 28 , 575, 196).
4), Pseudomonic acid (EB Chain et al.,
J. Chem. Soc., Perkin Trans. I, 294, 1977) and the like are known.

【0003】[0003]

【発明が解決すべき課題】現在、化学療法剤あるいは農
薬として、ペニシリンG、ストレプトマイシン、カナマ
イシン、クロラムフェニコール、テトラサイクリン、エ
リスロマイシン、リンコマイシン、アンホテリシンB、
カスガマイシン、ポリオキシンなどの化合物が用いられ
ているが、効力あるいは耐性菌の出現の問題から、より
効力を有する化合物の開発が求められている。
Presently, as chemotherapeutic agents or pesticides, penicillin G, streptomycin, kanamycin, chloramphenicol, tetracycline, erythromycin, lincomycin, amphotericin B,
Although compounds such as kasugamycin and polyoxin have been used, development of more potent compounds has been demanded due to the problem of efficacy or emergence of resistant bacteria.

【0004】[0004]

【課題を解決するための手段】本発明者らは、多種類の
土壌などの試料を採取して、それから分離される微生物
についてそれらの生産する化合物を探索したところ、シ
ュードモナス属に属す微生物が化合物を生産すること、
該微生物を適宜の栄養培地および培養条件で培養するこ
とにより該化合物を培養物中に蓄積させ得ることを見い
出し、本発明を完成した。以下、本発明を詳細に説明す
る。 本発明は、式化3
[Means for Solving the Problems] The inventors of the present invention collected samples of various types of soils and searched for the compounds produced by the microorganisms separated therefrom, and found that the microorganisms belonging to the genus Pseudomonas To produce,
The present invention has been completed by discovering that the compound can be accumulated in the culture by culturing the microorganism in an appropriate nutrient medium and culture conditions. Hereinafter, the present invention will be described in detail. The present invention uses the formula 3

【化3】 (式中、RはHまたはSCH3 を表す。)で表される化
合物(以下、RがHで表される化合物をT1801A、
RがSCH 3 で表される化合物をT1801Cと呼
ぶ)、式化4
[Chemical 3](In the formula, R is H or SCH3Represents ) Represented by
Compound (hereinafter, R 180 is a compound represented by H, T1801A,
R is SCH 3The compound represented by is called T1801C
B), formula 4

【化4】 (式中、RはHまたはSCH3 を表す。)で表される化
合物(以下、RがHで表される化合物をT1801B、
RがSCH 3 で表される化合物をT1801Dと呼
ぶ)、並びにシュードモナス属に属する上記化合物の生
産菌を培地に培養し培養物中に該化合物を蓄積させこれ
を採取することを特徴とする上記式化3および化4で表
される化合物の製造方法を提供する。
[Chemical 4](In the formula, R is H or SCH3Represents ) Represented by
Compound (hereinafter, R 180 is a compound represented by H, T1801B,
R is SCH 3The compound represented by is called T1801D
), And the above compounds belonging to the genus Pseudomonas
By culturing the producer in a medium and accumulating the compound in the culture,
Is represented by the formulas 3 and 4 above.
A method for producing the compound is provided.

【0005】本発明の化3および化4で表される化合物
の製造に使用する微生物としては、シュードモナス属に
属し、化3および化4で表される化合物を生産する能力
を有する微生物であればいずれも用いることができる。
該微生物の例としては、本発明者らが静岡県土壌より分
離した細菌 SC-1801株が挙げられる。
The microorganisms used in the production of the compounds represented by the chemical formulas 3 and 4 of the present invention are microorganisms belonging to the genus Pseudomonas and having the ability to produce the compounds represented by the chemical formulas 3 and 4. Either can be used.
An example of the microorganism is the bacterial strain SC-1801 isolated by the present inventors from soil in Shizuoka prefecture.

【0006】SC-1801株はシュードモナス属に属する菌
株であり、工業技術院微生物工業技術研究所に寄託を行
なった。(微工研菌寄第12327号、FERM P−
12327)。
[0006] The SC-1801 strain is a strain belonging to the genus Pseudomonas, and has been deposited with the Institute of Microbial Technology, Institute of Industrial Technology. (Ministry of Microbiology, No. 12327, FERM P-
12327).

【0007】本発明の方法において、化3および化4で
表される化合物を生産する微生物を培養する培地として
は、シュードモナス属微生物の培養に常用される炭素
源、窒素源、無機物等を含む各種の培地を使用すること
ができる。炭素源としては、グルコース、麦芽糖、デン
プン、デキストリン、グリセリン、糖蜜などである。窒
素源としては、ペプトン、酵母エキス、肉エキス、大豆
粉、コーンスティープリカー、綿実粉、乾燥酵母、カザ
ミノ酸、塩化アンモニウム、硫酸アンモニウム、硝酸ア
ンモニウム、硝酸ナトリウム、尿素などである。無機物
としては、カリウム、ナトリウム、マグネシウム、鉄、
マンガン等の塩類およびリン酸塩類、たとえば塩化カリ
ウム、塩化ナトリウム、硫酸マグネシウム、硫酸第一
鉄、硫酸マンガン、リン酸カリウム、リン酸ナトリウム
などである。培養は通常、好気的に行われ、通気撹拌培
養が好適である。培養温度は25〜35℃、好ましくは
28〜33℃で、pHは6〜8が好ましい。培養時間は
種々の条件によって異なるが、通常、15〜30時間程
度で培養物中に蓄積される化合物の量が最高に達する。
In the method of the present invention, the medium for culturing the microorganism producing the compounds represented by Chemical formulas 3 and 4 includes various carbon sources, nitrogen sources, inorganic substances and the like which are commonly used for culturing Pseudomonas microorganisms. Can be used. Carbon sources include glucose, maltose, starch, dextrin, glycerin, molasses and the like. Examples of the nitrogen source include peptone, yeast extract, meat extract, soybean powder, corn steep liquor, cottonseed powder, dry yeast, casamino acid, ammonium chloride, ammonium sulfate, ammonium nitrate, sodium nitrate, urea and the like. As inorganic substances, potassium, sodium, magnesium, iron,
Salts and phosphates such as manganese such as potassium chloride, sodium chloride, magnesium sulfate, ferrous sulfate, manganese sulfate, potassium phosphate, sodium phosphate and the like. Culturing is usually carried out aerobically, and aeration stirring culture is suitable. The culture temperature is 25 to 35 ° C, preferably 28 to 33 ° C, and the pH is preferably 6 to 8. The culturing time varies depending on various conditions, but usually the maximum amount of the compound accumulated in the culture reaches about 15 to 30 hours.

【0008】培養終了後の培養物からの化3および化4
で表される化合物の採取は、微生物の培養物より化合物
を分離精製する公知の手段を単独または組み合わせて行
うことができる。たとえば、不純物との溶解度の差を利
用する手段や、活性炭、シリカゲル、アルミナ、マクロ
ポーラス非イオン系樹脂等の各種の吸着剤の吸着親和力
の差を利用する手段、イオン交換樹脂による不純物の除
去手段などのいずれもが、それぞれ単独で、または組み
合わせて、あるいは反復して利用される。
Chemical formula 3 and chemical formula 4 from the culture after the completion of the culture
The compound represented by can be collected by a known means for separating and purifying the compound from the culture of the microorganism, alone or in combination. For example, means for utilizing the difference in solubility with impurities, means for utilizing the difference in adsorption affinity of various adsorbents such as activated carbon, silica gel, alumina, macroporous nonionic resins, etc., means for removing impurities by ion exchange resins Etc. are used individually, in combination, or repeatedly.

【0009】化3および化4で表される本発明の化合物
の構造は、同定分析、特に分光学的検討に基づいて決定
した。該物質の理化学的性質は、次のとおりである。 1.T1801A 式化5
The structures of the compounds of the present invention represented by Chemical formulas 3 and 4 were determined based on identification analysis, particularly spectroscopic examination. The physicochemical properties of the substance are as follows. 1. T1801A Formula 5

【化5】 外観:褐色油状 分子式:C9 122 S3 元素分析:実測値(%) C 43.45,H 5.01 ,S 38.
7 計算値(%) C 43.52,H 4.87,S 38.72 分子量:248(FD−MS) 高分解能質量分析:実測値(m/z ) 247.9992 計算値(m/z ) 247.9999 紫外可視吸収スペクトル(nm, イソプロパノール中):
212(sh), 240(sh)260(sh), 333 赤外吸収スペクトル(cm-1, KBr錠剤法):3396, 2924,
1558, 1418 1268, 1204, 974, 852 1H−NMR(δppm, CDCl3):2.32(S 3H), 2.36(S 3
H), 2.43(S 3H)6.64(S 1H), 6.83(S 1H), 6.93(S 1H)13 C−NMR(δppm, CDCl3):15.03(q), 19.73(q),
20.06(q)113.3(d), 120.4(s), 124.1(s)128.7(s), 148.
0(s), 151.5(s) 呈色反応:陽性 ヨウ素,塩化第二鉄- フェリシアン化
カリウム 陰性 ニンヒドリン,ドラゲンドロフ,エーリッヒ, ア
ニスアルデヒド TLC(シリカゲル):Rf 0.51 (トルエン−酢酸エ
チル(50:1)) HPLC:保持時間 17.7分(カラム:YMC-Pack AM-303
(4.6×250mm), 溶出液 :メタノール−水(60:40), 流速:0.65ml/ 分,検出波
長:220nm ) 2.T1801B 式化6
[Chemical 5] Appearance: Brown oil Molecular formula: C 9 H 12 O 2 S 3 Elemental analysis: Actual value (%) C 43.45, H 5.01, S 38.
7 Calculated value (%) C 43.52, H 4.87, S 38.72 Molecular weight: 248 (FD-MS) High resolution mass spectrometry: Actual value (m / z) 247.9992 Calculated value (m / z) 247.9999 UV-visible absorption spectrum (nm, In isopropanol):
212 (sh), 240 (sh) 260 (sh), 333 Infrared absorption spectrum (cm -1 , KBr tablet method): 3396, 2924,
1558, 1418 1268, 1204, 974, 852 1H-NMR (δppm, CDCl 3 ): 2.32 (S 3H), 2.36 (S 3
H), 2.43 (S 3H) 6.64 (S 1H), 6.83 (S 1H), 6.93 (S 1H) 13 C-NMR (δppm, CDCl 3 ): 15.03 (q), 19.73 (q),
20.06 (q) 113.3 (d), 120.4 (s), 124.1 (s) 128.7 (s), 148.
0 (s), 151.5 (s) Color reaction: Positive iodine, ferric chloride-potassium ferricyanide Negative ninhydrin, Dragendrov, Erich, anisaldehyde TLC (silica gel): Rf 0.51 (toluene-ethyl acetate (50: 1)) HPLC: retention time 17.7 minutes (column: YMC-Pack AM-303
(4.6 × 250 mm), eluent: methanol-water (60:40), flow rate: 0.65 ml / min, detection wavelength: 220 nm) 2. T1801B Formulation 6

【化6】 外観:緑色粉末 分子式:C9 102 3 元素分析:実測値(%) C 44.51,H 5.02 ,S 37.
8 計算値(%) C 43.88,H 4.09 ,S 39.04 分子量:246(FD−MS) 高分解能質量分析:実測値(m/z ) 245.9838 計算値(m/z ) 245.9842 紫外可視吸収スペクトル(nm, イソプロパノール中):
230, 377, 521 赤外吸収スペクトル(cm-1 , KBr錠剤法):3472,2928,
1646, 1626 1500, 1264, 1080, 854 1 H−NMR(δppm, CDCl3):2.29(S 3H), 2.58(S 3
H)2.68(S 3H), 6.27(S 1H)13 C−NMR(δppm, CDCl3):13.98(q), 18.03(q),
18.53(q)125.5(d), 142.3(s), 148.1(s)155.0(s), 177.
2(s), 177.8(s) 呈色反応:陽性 ヨウ素 陰性 塩化第二鉄- フェリシアン化カリウム,ニンヒド
リン,ドラゲンドロフ,エーリッヒ,アニスアルデヒド TLC(シリカゲル):Rf 0.41 (トルエン−酢酸エ
チル(50:1)) HPLC:保持時間 34.0 分(カラム:YMC-Pack AM-30
3 (4.6×250mm), 溶出液 :メタノール−水(60:40), 流速:0.65ml/ 分,検出波
長:220nm ) 3.T1801C 式化7
[Chemical 6] Appearance: Green powder Molecular formula: C 9 H 10 O 2 S 3 Elemental analysis: Actual value (%) C 44.51, H 5.02, S 37.
8 Calculated value (%) C 43.88, H 4.09, S 39.04 Molecular weight: 246 (FD-MS) High resolution mass spectrometry: Measured value (m / z) 245.9838 Calculated value (m / z) 245.9842 UV-visible absorption spectrum (nm, In isopropanol):
230, 377, 521 Infrared absorption spectrum (cm -1 , KBr tablet method): 3472, 2928,
1646, 1626 1500, 1264, 1080, 854 1 H-NMR (δppm, CDCl 3 ): 2.29 (S 3H), 2.58 (S 3
H) 2.68 (S 3H), 6.27 (S 1H) 13 C-NMR (δppm, CDCl 3): 13.98 (q), 18.03 (q),
18.53 (q) 125.5 (d), 142.3 (s), 148.1 (s) 155.0 (s), 177.
2 (s), 177.8 (s) Color reaction: positive iodine negative ferric chloride-potassium ferricyanide, ninhydrin, dragendrov, Erich, anisaldehyde TLC (silica gel): Rf 0.41 (toluene-ethyl acetate (50: 1)) HPLC: retention time 34.0 minutes (column: YMC-Pack AM-30
3 (4.6 x 250 mm), eluent: methanol-water (60:40), flow rate: 0.65 ml / min, detection wavelength: 220 nm) 3. T1801C Formulation 7

【化7】 外観:黄色粉末 分子式:C10142 4 元素分析:実測値(%) C 43.73,H 5.41 ,S 46.
3 計算値(%) C 40.79,H 4.79 ,S 43.55 分子量:294(FD−MS) 高分解能質量分析:実測値(m/z ) 293.9853 計算値(m/z ) 293.9876 紫外可視吸収スペクトル(nm, イソプロパノール中):
234(sh), 348 赤外吸収スペクトル(cm-1 , KBr錠剤法):3468,3344,
2924, 1380 1278, 1182, 976, 864 1 H−NMR(δppm, CDCl3):2.44(S 12H), 7.31(S
2H)13 C−NMR(δppm, CDCl3):19.07(q), 126.8(s),
151.7(s) 呈色反応:陽性 ヨウ素,塩化第二鉄-フェリシアン化
カリウム 陰性 ニンヒドリン,ドラゲンドロフ,エーリッヒ, ア
ニスアルデヒド TLC(シリカゲル):Rf 0.48 (トルエン−酢酸エ
チル(50:1)) HPLC:保持時間 38.5 分(カラム:YMC-Pack AM-30
3 (4.6×250mm), 溶出液 : メタノール−水(60:40), 流速:0.65ml/ 分, 検出波
長:220nm) 4.T1801D 式化8
[Chemical 7] Appearance: Yellow powder Molecular formula: C 10 H 14 O 2 S 4 Elemental analysis: Actual value (%) C 43.73, H 5.41, S 46.
3 Calculated value (%) C 40.79, H 4.79, S 43.55 Molecular weight: 294 (FD-MS) High resolution mass spectrometry: Measured value (m / z) 293.9853 Calculated value (m / z) 293.9876 UV-visible absorption spectrum (nm, In isopropanol):
234 (sh), 348 Infrared absorption spectrum (cm -1 , KBr tablet method): 3468,3344,
2924, 1380 1278, 1182, 976, 864 1 H-NMR (δppm, CDCl 3 ): 2.44 (S 12H), 7.31 (S
2H) 13 C-NMR (δppm, CDCl 3 ): 19.07 (q), 126.8 (s),
151.7 (s) Color reaction: Positive iodine, ferric chloride-potassium ferricyanide Negative ninhydrin, Dragendrov, Erich, anisaldehyde TLC (silica gel): Rf 0.48 (toluene-ethyl acetate (50: 1)) HPLC: retention time 38.5 Minute (column: YMC-Pack AM-30
3 (4.6 x 250 mm), eluent: methanol-water (60:40), flow rate: 0.65 ml / min, detection wavelength: 220 nm) 4. T1801D Formulation 8

【化8】 外観:黄色粉末 分子式:C10122 4 元素分析:実測値(%) C 42.51,H 4.62 ,S 37.
6 計算値(%) C 41.07,H 4.14 ,S 43.85 分子量:292(FD−MS) 高分解能質量分析:実測値(m/z ) 291.9724 計算値(m/z ) 291.9719 紫外可視吸収スペクトル(nm, イソプロパノール中):
392 赤外吸収スペクトル(cm-1 , KBr錠剤法):3488,2940,
1652, 1488 1418, 1224, 1128, 726 1H−NMR(δppm, CDCl3):2.55(S 12H)13 C−NMR(δppm, CDCl3):17.81(q), 145.7(s),
174.2(s) 呈色反応:陽性 ヨウ素 陰性 塩化第二鉄-フェリシアン化カリウム,ニンヒド
リン,ドラゲンドロフ,エーリッヒ,アニスアルデヒド TLC(シリカゲル):Rf 0.52 (トルエン−酢酸エ
チル(50:1)) HPLC:保持時間 76.3分(カラム:YMC-Pack AM-303
(4.6×250mm), 溶出液 :メタノール−水(60:40), 流速:0.65ml/ 分,検出波
長:220nm )
[Chemical 8] Appearance: Yellow powder Molecular formula: C 10 H 12 O 2 S 4 Elemental analysis: Actual value (%) C 42.51, H 4.62, S 37.
6 Calculated value (%) C 41.07, H 4.14, S 43.85 Molecular weight: 292 (FD-MS) High resolution mass spectrometry: Measured value (m / z) 291.9724 Calculated value (m / z) 291.9719 UV-visible absorption spectrum (nm, In isopropanol):
392 Infrared absorption spectrum (cm -1 , KBr tablet method): 3488,2940,
1652, 1488 1418, 1224, 1128, 726 1H-NMR (δppm, CDCl 3 ): 2.55 (S 12H) 13 C-NMR (δppm, CDCl 3 ): 17.81 (q), 145.7 (s),
174.2 (s) Color reaction: positive iodine negative ferric chloride-potassium ferricyanide, ninhydrin, dragendrov, Erich, anisaldehyde TLC (silica gel): Rf 0.52 (toluene-ethyl acetate (50: 1)) HPLC: retention time 76.3 Minute (column: YMC-Pack AM-303
(4.6 x 250 mm), eluent: methanol-water (60:40), flow rate: 0.65 ml / min, detection wavelength: 220 nm)

【0010】[0010]

【実施例】次に本発明の実施例を示すが、この実施例は
単なる一例を示すものであって、本発明を限定するもの
ではない。
EXAMPLES Next, examples of the present invention will be shown, but these examples are merely examples and do not limit the present invention.

【0011】実施例1 シュードモナス・エスピー SC-1801の1白金耳を大型試
験管(2.2 ×200mm )中の液体培地(ペプトン 1%、肉
エキス0.3%、塩化ナトリウム 0.5%、pH7.0 )10ml
に接種し、30℃で18時間振とう培養した。この培養液の
1mlを 500ml容坂口フラスコ中の液体培地(ペプトン 1
%、肉エキス 0.3%、塩化ナトリウム 0.5%、pH7.0
)100ml に接種し、30℃で 8時間振とう培養した。こ
れを30L容ジャーファーメンター中の15Lの本培養用培
地(ペプトン 1%、酵母エキス 0.5%、シリコンオイル
KS-66(信越化学)0.03%、pH 7.0)に 1%の割合で
接種し、温度30℃、通気量7.5 L/分、撹拌速度 250rp
m の条件で18時間通気撹拌培養した。得られた培養液14
Lを遠心分離により菌体と培養上清とに分離し、培養上
清画分を4Lの酢酸エチルで2回抽出し、得られた抽出
液計8Lを減圧濃縮した。濃縮液を 100mlのトルエンで
抽出し、抽出液をシリカゲルカラム(あらかじめトルエ
ンで平衡化)の上端に添加した。カラムを最初にトルエ
ン、次いでトルエン−酢酸エチル(98:2)で溶出し、活
性画分を回収して75mgの油状物を得た。これを10mlのヘ
キサンに溶解し、あらかじめヘキサン−イソプロパノー
ル(1000 :1 )で平衡化したローバーカラム(LiChrop
repCN, size B, メルク)にアプライし、同溶媒で溶出
し、活性画分を回収して40mgの粗物質を得た。これを25
mlのメタノール−水(60:40)に溶解し、あらかじめメ
タノール−水(60:40)で平衡化した逆相HPLCカラ
ム(μBondasphere,15 μ, 5 ×30cm, ウォーターズ)
にアプライし、同溶媒で溶出した。この時、溶出液の流
速は50ml/分、検出は220nm における紫外吸収とした。
保持時間35、68、79、138 分の各溶出画分を分取し、減
圧下蒸発乾固して、溶出順にT1801A、T1801
B、T1801C、T1801Dの精製品をそれぞれ5.
0 、1.5 、1.7 、0.7mg 得た。得られた各精製品の諸性
質は前述した各物質の理化学的性質と一致した。
Example 1 One platinum loop of Pseudomonas sp. SC-1801 was placed in a large test tube (2.2 x 200 mm) in a liquid medium (peptone 1%, meat extract 0.3%, sodium chloride 0.5%, pH 7.0) 10 ml.
The cells were inoculated and cultured with shaking at 30 ° C for 18 hours. Of this culture
1 ml to liquid medium (Peptone 1 in a 500 ml Sakaguchi flask)
%, Meat extract 0.3%, sodium chloride 0.5%, pH 7.0
) 100 ml was inoculated and cultured at 30 ° C for 8 hours with shaking. 15 L of main culture medium in a 30 L jar fermenter (peptone 1%, yeast extract 0.5%, silicone oil)
KS-66 (Shin-Etsu Chemical) 0.03%, pH 7.0) was inoculated at a ratio of 1%, temperature 30 ° C, aeration rate 7.5 L / min, stirring speed 250rp
The cells were cultured under aeration and stirring for 18 hours under the condition of m 2. The obtained culture solution 14
L was separated into bacterial cells and culture supernatant by centrifugation, the culture supernatant fraction was extracted twice with 4 L of ethyl acetate, and a total of 8 L of the obtained extract was concentrated under reduced pressure. The concentrate was extracted with 100 ml of toluene, and the extract was added to the upper end of a silica gel column (preliminarily equilibrated with toluene). The column was first eluted with toluene then toluene-ethyl acetate (98: 2) and the active fractions were collected to give 75 mg of an oil. This was dissolved in 10 ml of hexane and preliminarily equilibrated with hexane-isopropanol (1000: 1) on a Rover column (LiChrop
repCN, size B, Merck) and eluted with the same solvent, and the active fraction was collected to obtain 40 mg of a crude substance. 25 this
Reversed-phase HPLC column (μBondasphere, 15 μ, 5 × 30 cm, Waters) dissolved in ml of methanol-water (60:40) and equilibrated with methanol-water (60:40) in advance.
And then eluted with the same solvent. At this time, the flow rate of the eluate was 50 ml / min, and the detection was ultraviolet absorption at 220 nm.
Elution fractions with retention times of 35, 68, 79, and 138 were collected, evaporated to dryness under reduced pressure, and T1801A and T1801 in the order of elution.
Purified products of B, T1801C and T1801D are each 5.
0, 1.5, 1.7 and 0.7 mg were obtained. The properties of each of the obtained purified products were in agreement with the physicochemical properties of each substance described above.

【0012】実施例2 抗菌・抗真菌活性 各種微生物に対する最小生育阻止濃度(MIC)を寒天
平板希釈法により測定した。結果を表1に示す。
Example 2 Antibacterial and antifungal activity The minimum inhibitory concentration (MIC) against various microorganisms was measured by the agar plate dilution method. The results are shown in Table 1.

【表1】 [Table 1]

【0013】[0013]

【発明の効果】本発明の化合物は抗菌・抗真菌活性を有
し、医薬用または農薬用化合物として利用される。
The compound of the present invention has antibacterial / antifungal activity and is used as a compound for pharmaceuticals or agricultural chemicals.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 (C12P 11/00 C12R 1:38) (72)発明者 加藤 三典 大阪府大阪市此花区春日出中3丁目1番98 号 住友化学工業株式会社内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Internal reference number FI technical display location (C12P 11/00 C12R 1:38) (72) Inventor Sannori Kato Kasuga, Konohana-ku, Osaka-shi, Osaka Ichinaka 3-chome No. 98 Sumitomo Chemical Co., Ltd.

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 式化1 【化1】 (式中、RはHまたはSCH3 を表す。)で表される化
合物
1. Formula 1 (In the formula, R represents H or SCH 3. )
【請求項2】 式化2 【化2】 (式中、RはHまたはSCH3 を表す。)で表される化
合物
2. Formula 2 (In the formula, R represents H or SCH 3. )
【請求項3】シュードモナス属に属し、請求項1あるい
は請求項2記載の化合物を生産する能力を有する微生物
を培養し、培養物中にこれらの化合物を生成蓄積させ、
これを採取することを特徴とする式化1あるいは式化2
の化合物の製造方法。
3. A microorganism belonging to the genus Pseudomonas and capable of producing the compound according to claim 1 or 2 is cultured, and these compounds are produced and accumulated in the culture,
Formula 1 or Formula 2 characterized by collecting this
A method for producing the compound of.
【請求項4】化合物を生産する能力を有する微生物がシ
ュードモナス・エスピー SC-1801である請求項3項記載
の製造方法。
4. The method according to claim 3, wherein the microorganism capable of producing a compound is Pseudomonas sp. SC-1801.
JP19776291A 1991-08-07 1991-08-07 Compound and its production Pending JPH0539257A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP19776291A JPH0539257A (en) 1991-08-07 1991-08-07 Compound and its production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP19776291A JPH0539257A (en) 1991-08-07 1991-08-07 Compound and its production

Publications (1)

Publication Number Publication Date
JPH0539257A true JPH0539257A (en) 1993-02-19

Family

ID=16379932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP19776291A Pending JPH0539257A (en) 1991-08-07 1991-08-07 Compound and its production

Country Status (1)

Country Link
JP (1) JPH0539257A (en)

Similar Documents

Publication Publication Date Title
EP0491956A1 (en) Reveromycin a, production thereof, and antitumor drug and fungicide
JPH0539257A (en) Compound and its production
US4587237A (en) Mycotrienin-related compounds
JPH0670019B2 (en) New antibiotic SF2197C substance and its manufacturing method
US5536850A (en) Substance DC114-A1
JPH05294952A (en) Antibiotic substance wap-4068, its derivative and production thereof
JP3030896B2 (en) WB968 substance group and production method thereof
JPH05255184A (en) New compound ilicicolinic acid a or b
JP2858939B2 (en) Antibiotics AB3217A, AB3217B and AB3217C and their production
JPH0415788B2 (en)
JPH0639480B2 (en) New macrolide antibiotic M119
JPS5813392A (en) Novel antibiotic substance, sf-2107a2, and its preparation
AU620595B2 (en) Process for the preparation of macrolide compounds
JPH0353315B2 (en)
JPS59181294A (en) Antibiotic substance ptl-448, its derivative and their preparation
JPH0343266B2 (en)
JPS5918035B2 (en) Antibiotic AB-85
JPH04120087A (en) New antitumor antibiotic substance sf2587c and production thereof
JPH03103185A (en) Production of isoolefin compound
WO2001062950A1 (en) Novel antibiotic wk-6150 and process for producing the same
JPH0764851B2 (en) Reveromycin B, C, and D, production method thereof, and antitumor agent and antifungal agent
JPH0474357B2 (en)
JPH06199882A (en) New antifungal antibiotic substance w7176b and w7176c and production thereof
JPH05271201A (en) Phencomycin, its preparation and use
JPH09169689A (en) New antibiotic k93-5305 and its production